The Journal of Pediatrics
Volume 149, Issue 3 , Pages 291-292 , September 2006

Revisiting steroids in the primary treatment of acute Kawasaki disease

  • Jane C. Burns, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Dr Jane C. Burns, Dept. of Pediatrics, UCSD School of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0830.

References 

  1. Shulman ST . Is there a role for corticosteroids in Kawasaki disease? . J Pediatr . 2003;142:601–603
  2. Kawasaki T . [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children] . Arerugi . 1967;16:178–222 Shike H, Burns JC, Shimizu C. English translation of Dr. Tomisaku Kawasaki’s original report of fifty patients in 1967 (Japanese). Pediatr Inf Dis J. 2002;21:993. Article plus additional online files.
  3. Inoue Y , Okada Y , Tomomasa T , Takeuchi K , Morikawa A . A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease (clinical course and coronary artery outcome) . J Pediatr . 2006;149:336–341
  4. Newburger JW , Takahashi M , Beiser AS , Burns JC , Bastian J , Chung KJ , et al.   A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome . N Engl J Med . 1991;324:1633–1639
  5. Klassen TP , Rowe PC , Gafni A . Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome . J Pediatr . 1993;122:538–542
  6. de Zorzi A , Colan SD , Gauvreau K , Baker AL , Sundel RP , Newburger JW . Coronary artery dimensions may be misclassified as normal in Kawasaki disease . J Pediatr . 1998;133:254–258
  7. Burns JC , Shimizu C , Gonzalez E , Kulkarni H , Patel S , Shike H , et al.   Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease . J Infect Dis . 2005;192:344–349
  8. Minami T , Suzuki H , Takeuchi T , Uemura S , Sugatani J , Yoshikawa N . A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease . J Pediatr . 2005;147:78–83
  9. Newburger JW , Takahashi M , Burns JC , Beiser AS , Chung KJ , Duffy CE , et al.   The treatment of Kawasaki syndrome with intravenous gamma globulin . N Engl J Med . 1986;315:341–347
  10. Kobayashi T , Inoue Y , Takeuchi K , Okada Y , Tamura K , Tomomasa T , et al.   Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease . Circulation . 2006;113:2606–2612
  11. Muta H , Ishii M , Furui J , Nakamura Y , Matsuishi T . Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease . Acta Paediatr . 2006;95:189–193

PII: S0022-3476(06)00680-9

doi: 10.1016/j.jpeds.2006.07.016

The Journal of Pediatrics
Volume 149, Issue 3 , Pages 291-292 , September 2006

Article Tools